Open AccessModeling Favipiravir Antiviral Efficacy Against Emerging Viruses: From Animal Studies to Clinical Trials
Author(s) -
Madelain Vincent,
Mentré France,
Baize Sylvain,
Anglaret Xavier,
Laouénan Cédric,
Oestereich Lisa,
Nguyen Thi Huyen Tram,
Malvy Denis,
Piorkowski Géraldine,
Graw Frederik,
Günther Stephan,
Raoul Hervé,
Lamballerie Xavier,
Guedj Jérémie
Publication year - 2020
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1002/psp4.12510
Subject(s) - favipiravir , ebola virus , context (archaeology) , virology , virus , clinical trial , antiviral drug , regimen , medicine , biology , disease , bioinformatics , covid-19 , infectious disease (medical specialty) , paleontology , pathology
In 2014, our research network was involved in the evaluation of favipiravir, an anti‐influenza polymerase inhibitor, against Ebola virus. In this review, we discuss how mathematical modeling was used, first to propose a relevant dosing regimen in humans, and then to optimize its antiviral efficacy in a nonhuman primate (NHP) model. The data collected in NHPs were finally used to develop a model of Ebola pathogenesis integrating the interactions among the virus, the innate and adaptive immune response, and the action of favipiravir. We conclude the review of this work by discussing how these results are of relevance for future human studies in the context of Ebola virus, but also for other emerging viral diseases for which no therapeutics are available.